Recent News

• 06.04.2025 - 2025 Jefferies Global Healthcare Conference
• 06.03.2025 - William Blair 45th Annual Growth Stock Conference
• 05.27.2025 - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
• 05.14.2025 - ARS Pharmaceuticals’ 1Q 2025 Earnings Call
• 05.14.2025 - ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
• 05.07.2025 - ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
• 05.05.2025 - ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
• 05.02.2025 - ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Recent Filings

• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2025 - 144 Report of proposed sale of securities
• 05.20.2025 - 144 Report of proposed sale of securities
• 05.20.2025 - 144 Report of proposed sale of securities
• 05.14.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - 8-K Current report
• 05.02.2025 - 8-K Current report